×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
invoX acquires bispecific firm F-Star for $161m - BioProcess Insider
BioProcess International
invoX Pharma will pay $161 million to acquire F-Star, a Cambridge, UK clinical stage company developing bispecific drugs for immunotherapies.
1 month ago
Takeda adds another F-Star collab to constellation, this time for $1B in biobucks
Fierce Biotech
Takeda and F-Star Therapeutics are tacking on another bispecific antibody deal worth $1 billion in potential milestones, marking the third...
9 months ago
Takeda, F-star Sign Potential $1B Immuno-Oncology Agreement
BioSpace
The companies have signed two other pacts over the last year. In the latest deal, Takeda gains access to F-star's platform to produce...
9 months ago
F-star, an invoX Company, Announces Strategic Collaboration and Licence Agreement with Takeda to Discover and ...
GlobeNewswire
LONDON, July 05, 2023 (GLOBE NEWSWIRE) -- F-star Therapeutics, an invoX company (“F-star”), today announced that it has entered into a...
9 months ago
F-star and Takeda enter antibody development deal
Pharmaceutical Technology
F-star Therapeutics and Takeda have signed a strategic discovery partnership and licence deal to develop multi-specific immunotherapies.
9 months ago
Takeda, F-star Therapeutics Partner To Advance Immunotherapies
Contract Pharma
Takeda, F-star Therapeutics Partner to Advance Immunotherapies. To jointly research and develop antibodies for new immuno-oncology targets...
10 months ago
F-star Therapeutics announces new data on tetravalent bispecific antibody for advanced treatment-refractory solid tumors
BioWorld MedTech
Along with preliminary first-in-human data, investigators from F-star Therapeutics Inc. recently presented preclinical results for the...
10 months ago
Takeda and F-star announce immunotherapy partnership worth over $1bn
PMLiVE
Takeda and F-star Therapeutics have announced a strategic collaboration and licence agreement focused on developing next-generation...
9 months ago
F-star Therapeutics Completes Combination with Spring Bank Pharmaceuticals
PR Newswire
The combined company is now headquartered out of F-star's existing facilities in Cambridge, U.K. and Cambridge, MA. Spring Bank has been re-...
41 months ago